GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration support advancing CAP-003 into clinical development in 1H25.
Neuron23 today announced the publication of a manuscript in the Proceedings of the National Academy of Sciences (PNAS), which explores the role of tyrosine kinase 2 (TYK2) inhibition in neuroinflammation, microglia and astrocyte regulation, and modulation of various biomarkers of neuroinflammation in Experimental Autoimmune Encephalomyelitis (EAE), a widely utilized model of multiple sclerosis (MS) and neuroinflammation.
Data from the Phase 1 healthy volunteer study of NEU-411 will be presented at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), taking place April 1-5 in Vienna.
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s total committed capital to $180 million
Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease
